Advanced or Metastatic Solid Tumors Clinical Trials

43 recruitingLast updated: June 18, 2026

There are 43 actively recruiting advanced or metastatic solid tumors clinical trials across 19 countries. Studies span Phase 1, Phase 2. Top locations include Boston, Massachusetts, United States, Nashville, Tennessee, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Advanced or Metastatic Solid Tumors Trials at a Glance

43 actively recruiting trials for advanced or metastatic solid tumors are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 1 with 41 trials, with the heaviest enrollment activity in Boston, Nashville, and Houston. Lead sponsors running advanced or metastatic solid tumors studies include Hanmi Pharmaceutical Company Limited, Chinese PLA General Hospital, and Avistone Biotechnology Co., Ltd..

Browse advanced or metastatic solid tumors trials by phase

Treatments under study

About Advanced or Metastatic Solid Tumors Clinical Trials

Looking for clinical trials for Advanced or Metastatic Solid Tumors? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Advanced or Metastatic Solid Tumors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Advanced or Metastatic Solid Tumors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 43 trials

Recruiting
Phase 1Phase 2

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

Advanced or Metastatic Solid Tumors
Takeda223 enrolled15 locationsNCT07205718
Recruiting
Phase 1

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled35 locationsNCT07094113
Recruiting
Phase 1

A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors
Shanghai EpimAb Biotherapeutics Co., Ltd.50 enrolled1 locationNCT07607054
Recruiting
Phase 1

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

MelanomaNon-small Cell Lung CancerThyroid Cancer+10 more
Pfizer124 enrolled82 locationsNCT05538130
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 1

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Colorectal, CancerPancreatic CancerGastric Cancer+1 more
ArriVent BioPharma, Inc.405 enrolled20 locationsNCT07066657
Recruiting
Phase 1

A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.189 enrolled14 locationsNCT06248411
Recruiting
Phase 1Phase 2

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Biocity Biopharmaceutics Co., Ltd.111 enrolled1 locationNCT07469774
Recruiting
Phase 1

GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.

Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated
Changchun GeneScience Pharmaceutical Co., Ltd.186 enrolled1 locationNCT07407504
Recruiting
Phase 1

A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors With Homozygous MTAP Deletion
Shouyao Holdings (Beijing) Co. LTD122 enrolled1 locationNCT07469982
Recruiting
Phase 1

A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients

Advanced or Metastatic Solid Tumors
Kangabio AUSTRALIA LTD PTY57 enrolled3 locationsNCT07260305
Recruiting
Phase 1

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.63 enrolled15 locationsNCT06307795
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1Phase 2

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Advanced or Metastatic Solid Tumors
Beijing Biotech60 enrolled1 locationNCT07510828
Recruiting
Phase 1Phase 2

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Breast CancerColorectal, CancerGastric Cancer+10 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1

A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.96 enrolled5 locationsNCT06716138
Recruiting
Phase 1

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited245 enrolled10 locationsNCT06234397
Recruiting
Phase 2

A Study of YL202 in Patients With Advanced Solid Tumors

Colorectal, CancerCervical CancerNon-small Cell Lung Cancer+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.100 enrolled1 locationNCT07202364
Recruiting
Phase 1

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Non-small Cell Lung CancerNSCLCAdvanced or Metastatic Solid Tumors
Incendia Therapeutics270 enrolled11 locationsNCT05753722
Recruiting
Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Breast CancerColorectal, CancerOvarian Cancer+6 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587